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Langerhans cells (LCs) represent a unique DC 
subset in the epidermis. Langerin (CD207) is a 
C-type  lectin  predominantly  expressed  by   
LCs but also some murine CD8+ LN DCs 
(Takahara et al., 2002; Valladeau et al., 2002; 
Douillard  et  al.,  2005;  Kissenpfennig  et  al., 
2005). New subsets of Langerin+ dermal DCs 
(dDCs), independent from epidermal LCs in 
transit, have been identified (Bursch et al., 2007; 
Ginhoux et al., 2007; Poulin et al., 2007). The 
dermis contains two more subsets of Langerin+ 
dDCs (distinguished by differential CD103 ex-
pression) and two subsets of Langerinneg dDCs 
that differ in CD11b expression (Henri et al., 
2010). Both Langerin+ dDC subsets constitute 
3% of all dDCs, whereas Langerinneg CD11b+ 
dDCs represent 66% of all dDCs, and Lan-
gerinneg  CD11bneg  dDCs  are  less  frequent 
(16%). Thus, murine skin contains at least five 
phenotypically distinct DC populations, i.e., 
epidermal  LCs  and  two  Langerin+  and  two 
Langerinneg dDC subsets, which may also differ 
in function, e.g., in their ability to (cross-) present 
antigen (Kaplan et al., 2008; Nagao et al., 2009; 
Henri et al., 2010).
In  experimental  cutaneous  leishmaniasis, 
parasite-infected DCs mediate the induction of 
protective immunity by producing IL-12 (von 
Stebut et al., 1998) and migratory skin DCs are 
considered to play an important role in priming 
T cell responses against Leishmania major. Origi-
nally, LCs had been thought to be essential for 
the control of cutaneous leishmaniasis because 
antigen-pulsed LCs can establish protective im-
munity (Moll et al., 1993). However, more recent 
studies demonstrated that other DC subtypes, in-
cluding CD11b+ LN-resident DCs and CD8neg 
Langerinneg  dDCs,  can  be  infected  and  act  as 
principal antigen-presenting cells in leishmaniasis 
(Misslitz et al., 2004; Ritter et al., 2004; Iezzi   
et al., 2006). Furthermore, during Leishmania in-
fection, monocyte-derived DCs form at the in-
fection site, which controls the induction of a 
protective Th1 response (León et al., 2007).
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Migratory skin dendritic cells (DCs) are thought to play an important role in priming T cell 
immune responses against Leishmania major, but DC subtypes responsible for the induction 
of protective immunity against this pathogen are still controversial. In this study, we ana-
lyzed the role of Langerin+ skin-derived DCs in the Leishmania model using inducible in vivo 
cell ablation. After physiologically relevant low-dose infection with L. major (1,000 para-
sites), mice depleted of all Langerin+ DCs developed significantly smaller ear lesions with 
decreased parasite loads and a reduced number of CD4+ Foxp3+ regulatory T cells (T reg cells) 
as compared with controls. This was accompanied by increased interferon  production in 
lymph nodes in the absence of Langerin+ DCs. Moreover, selective depletion of Langerhans 
cells (LCs) demonstrated that the absence of LCs, and not Langerin+ dermal DC, was  
responsible for the reduced T reg cell immigration and the enhanced Th1 response, result-
ing in attenuated disease. Our data reveal a unique and novel suppressive role for epidermal 
LCs in L. major infection by driving the expansion of T reg cells. A better understanding of 
the various roles of different DC subsets in cutaneous leishmaniasis will improve the devel-
opment of a potent therapeutic/prophylactic vaccine.
©  2011  Kautz-Neu  et  al.  This  article  is  distributed  under  the  terms  of  an   
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six   
months after the publication date (see http://www.rupress.org/terms). After   
six months it is available under a Creative Commons License (Attribution– 
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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IL-12 is primarily released by infected DCs (von Stebut   
et al., 1998; Ahuja et al., 1999; Sacks and Noben-Trauth, 
2002) and is critical to mediate protection (Berberich et al., 
2003). In this study, Langerin+ DCs did not contribute to 
this IL-12 release (Fig. 1 C). Importantly, IFN- production 
was significantly increased in DT-treated Langerin-DTR 
mice as compared with controls (57 ± 6 vs. 31 ± 8 ng/ml,   
P = 0.021). No difference was observed in IL-10 production 
in week 6 after infection (Fig. 1 C). IL-4 levels in LN super-
natants were low as expected (C57BL/6 Leishmania-resistant 
background) without differences between treatment groups.
Our findings demonstrate a novel and unexpected sup-
pressive role of Langerin+ DCs, which is only visible in the 
physiologically relevant low-dose infection model. When we 
used high-dose inocula (intradermal infection with 2 × 105 
metacyclic promastigotes) in Langerin+ DC-depleted mice, 
we did not observe comparable changes regarding lesion   
Because an effective Leishmania vaccine does not exist and 
(skin) DCs are critical regulators of the anti-Leishmania im-
mune response, DCs are attractive targets for immunothera-
peutic  approaches.  Thus,  it  is  essential  to  understand  the 
precise role of a particular DC subset in leishmaniasis. The 
development of knock-in mice expressing a diphtheria toxin 
(DT) receptor (DTR) cDNA under control of the langerin 
promoter allows us to unravel the in vivo dynamics and   
function of Langerin+ DCs in general and LCs in particular 
(Bennett et al., 2005; Kissenpfennig et al., 2005; Kaplan   
et al., 2008). Application of DT to Langerin-DTR mice rap-
idly eliminates all Langerin+ cells from epidermis, dermis, and 
skin-draining LN.
In a previous study, subcutaneous high-dose infections of 
DT-treated Langerin-DTR mice with 3 × 106 stationary 
phase L. major parasites into foot pads showed that depletion 
of LCs had no effect on disease outcome and parasite clear-
ance (Brewig et al., 2009). In the present study, we extend 
these findings using physiological low-dose infections with 
only infectious stage parasites (1,000 metacyclic promasti-
gotes) and intradermal ear inoculation (Belkaid et al., 2000) 
to reveal for the first time that LCs have a regulatory function 
in an infectious disease model. Moreover, better parasite 
clearance was linked with enhanced Th1 (more IFN-), re-
duced lesional T reg cell numbers, and less IL-10 in the ab-
sence of LCs. With regard to vaccine development strategies, 
our results strongly suggest the use of approaches that aim   
to circumvent activation or targeting of LCs during anti-
Leishmania immunization.
RESULTS AND DISCUSSION
Conditional ablation of Langerin+ DCs leads to enhanced 
protective immunity against L. major infection
Langerin-DTR mice were injected i.p. with DT to deplete 
all Langerin+ DCs, including epidermal LCs, Langerin+ 
dDCs, and LN-resident Langerin+ DCs (Fig. S1, A and B; 
Bennett et al., 2005, 2007). 2 d after DT treatment, mice 
were infected intradermally with 1,000 metacyclic L. major 
promastigotes and were subsequently treated weekly with 
DT to maintain depletion of all Langerin+ cells. DT treat-
ment was well tolerated without any side effects as reported 
previously (Bennett et al., 2005; Bennett and Clausen, 2007). 
After infection, mice depleted of Langerin+ cells developed 
significantly smaller ear lesions as compared with PBS-treated 
controls (Fig. 1 A). Lesion sizes in the PBS control group 
were similar to those in C57BL/6 wild-type mice (Fig. S1 C). 
Decreased lesion sizes in Langerin-DTR + DT mice cor-
related with significantly lower parasite burdens in infected 
ears at week 6 after infection (5.3 ± 1.9 × 104 in DT-treated 
mice compared with 3.9 ± 1.105 in control mice, n = 8,   
P = 0.008; Fig. 1 B). Spleen parasite burdens were very low 
in both groups without significant differences.
We next assessed the cytokine profile 6 wk after infec-
tion. IFN-, IL-12, and IL-10 levels were determined after 48 h 
of restimulation of skin-draining LN cells with soluble Leishma-
nia antigen (SLA). In Leishmania infections, Th1-inducing   
Figure 1.  Depletion of Langerin+ DC improves disease outcome in 
mice infected with L. major. (A) Groups of three to five animals of DT- 
or PBS-treated Langerin-DTR mice were infected intradermally with 103 
metacyclic L. major promastigotes. DT or PBS treatment was performed 48 h 
before infection and repeated weekly. Lesion development was assessed 
(mean ± SEM), and pooled data from five or more independent experi-
ments are shown. (B) Numbers of parasites in ear lesions (left) and 
spleens (right) were quantified using limiting dilution assays at 6 wk after 
infection. Mean parasite loads are shown as bars, and individual parasite 
counts/ear or spleen as squares (PBS) and triangles (DT). Results are rep-
resentative of three independent experiments. (C) Antigen-specific cyto-
kine release by LN cells from 6-wk-infected mice was determined by ELISA 
after restimulation with SLA. Pooled data from two independent experi-
ments are shown. Values are mean ± SEM of 9–10 mice per time point  
(*, P ≤ 0.05; **, P ≤ 0.02; ***, P ≤ 0.002, difference to PBS control mice).JEM VOL. 208, May 9, 2011  887
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Collectively, using two different experimental approaches, our 
results demonstrate that depletion of LCs alone is sufficient to 
significantly reduce lesion sizes, indicating that LCs are the 
relevant DC subset suppressing efficient effector T cell (T eff 
cell) responses in this skin infection model.
Depletion of Langerin+ DCs reduces the number  
of regulatory T cells in L. major–infected ears
To elucidate the mechanism underlying the observed pheno-
type, we analyzed the CD4+ and CD8+ T cell populations in 
skin draining LN and infected ears in the presence or absence 
of Langerin+ cells biweekly after infection. No difference was 
development, parasite burdens, and cytokine profile (Fig. S2, 
A–C). This is consistent with data from Brewig et al. (2009), 
who used high doses of parasites (3 × 106) and subcutaneous 
inoculation,  which  masques  any  regulatory  role  of  LCs  in   
experimental leishmaniasis. Thus, other differences between 
that prior study and ours (other mouse strain, different route 
of parasite inoculation, and distinct parasite strains) are not 
responsible for the incongruent results.
LCs, not Langerin+ dDCs, suppress the anti-Leishmania response
As both types of skin DC, i.e., epidermal LCs and Langerin+ 
dDCs, are depleted by continuous DT treatment in our ex-
periments, it was not clear which cell type was responsible for 
the suppressive effects shown in Fig. 1. To analyze the role of 
LCs in more detail, we performed timed toxin treatments. 
After conditional ablation of Langerin+ DCs in vivo using a 
single injection of DT, Langerin+ dDCs started reappearing 
already at days 3–5 and were largely restored by day 14   
(Fig. S3 A; Noordegraaf et al., 2010), whereas this one-time 
DT administration depleted LCs for at least 2–4 wk with, oc-
casionally, very few cells detectable at 2 wk and only partial 
reconstitution as late as 10 wk after DT (Fig. S3 B; Bennett 
et al., 2005). We next took advantage of this differential re-
population kinetics of LCs and Langerin+ dDCs to discrimi-
nate between the two DC subsets. Specifically, Langerin-DTR 
mice were injected once with DT 2 wk before Leishmania 
inoculation such that essentially all LCs were still depleted 
(Bennett et al., 2005), whereas the majority of Langerin+ 
dDCs had already reappeared (Fig. S3 A; Noordegraaf et al., 
2010). Upon selective depletion of LCs alone, lesion sizes 
were significantly reduced as compared with controls, with 
the largest difference in week 7 (9.6 ± 1 and 5 ± 0.6 mm3 in 
PBS and DT 1× groups, respectively, P = 0.0001; Fig. 2 A). 
No obvious difference between the two different DT treat-
ment protocols was seen.
To confirm these results, we generated hematopoietic BM 
chimeras. C57BL/6 donor BM was used to reconstitute le-
thally irradiated (9 Gray) Langerin-DTR recipient mice.   
Epidermal LCs are radioresistant and remain of host (Langerin-
DTR) origin after irradiation and BM transplantation. In   
contrast, all other DC subtypes are radiosensitive and replaced 
by donor-derived cells (C57BL/6). The resulting chimeric 
animals were treated once with DT 48 h before L. major  
infection, causing selective depletion of LCs (Fig. S3 C). 
Subsequently, mice were infected with low-dose inocula of   
L.  major  and  lesion  development  was  assessed  weekly.  As 
shown in Fig. 2 B, selective depletion of LCs resulted in sig-
nificantly reduced lesion sizes. In contrast, in irradiated 
C57BL/6 mice reconstituted with Langerin-DTR BM, treat-
ment with DT led to depletion of all Langerin+ dDCs, except 
LCs (Fig. S3 C). Interestingly, in these mice, lesion develop-
ment was somewhat worsened as compared with controls, but 
the differences were not significant (Fig. 2 C). Moreover, these 
experiments ruled out an unspecific DT-induced phenomenon, 
as lesion sizes were only reduced after selective depletion of 
LCs but not after DT-mediated depletion of Langerin+ dDCs. 
Figure 2.  Selective depletion of LC leads to reduced lesion vol-
umes. (A) Groups of Langerin-DTR mice were injected i.p. with PBS or DT. 
2 wk later, mice were infected with 103 L. major parasites per ear. A third 
group was injected i.p. with DT 48 h before Leishmania infection and 
subsequently treated with DT once per week for the entire course of in-
fection. Pooled data from three independent experiments are shown  
(n ≥ 8 mice/group; +, statistical differences between PBS and DT 1× treat-
ment; *, statistical differences between PBS and DT weekly; x, statistical 
differences between DT 1× and DT weekly; *,+,x, P ≤ 0.05; **,++, P ≤ 0.02; 
***,+++, P ≤ 0.002). (B) Langerin-DTR mice were lethally irradiated with  
9 Gray, adoptively transferred with C57BL/6 BM (5 × 106 cells/mouse i.v.), 
and rested for 6 wk. Mice were treated once with DT or PBS 48 h before 
infection for the selective depletion of LC and infected with physiologi-
cally relevant low-dose inocula of L. major (103 metacyclic promastigotes).   
(C) C57BL/6 (recipient) mice were lethally irradiated with 9 Gray and 
adoptively transferred with Langerin-DTR (donor) BM for the depletion of 
Langerin+ dDC. DT- or PBS-treated chimeras were infected with 103 meta-
cyclic L. major promastigotes. DT and PBS treatment was repeated weekly. 
In B and C, pooled data from two independent experiments are depicted. 
Lesion development was calculated as ellipsoid (mean ± SEM; +, P ≤ 0.05; 
++, P ≤ 0.02; +++, P ≤ 0.002).888 Regulatory function of LCs in leishmaniasis | Kautz-Neu et al.
differences in IFN- production between weeks 5 and 7 (and 
not in the silent phase of infection).
In a separate set of experiments, we assessed if selective de-
pletion of LCs leads to similar results. As indicated in Fig. 3 C, 
significantly reduced numbers of CD4+ Foxp3+ T reg cells 
were observed in the ears of both DT-treated groups (e.g., 
week 7: PBS, 12.4 ± 1.9 × 103; DT 1×, 6.9 ± 1.5 × 103; and 
DT weekly, 6.5 ± 1.3 × 103, P = 0.049 and P = 0.016, respec-
tively, n ≥ 14), indicating that LCs alone are sufficient for T reg 
cell expansion in vivo. In addition, similar to continuous DT 
treatment, the IFN- production and IFN-/IL-4 ratio were 
significantly increased in the DT 1× treatment group in com-
parison with PBS controls in week 7 (Fig. 3 D).
Because T reg cells exert their suppressive function largely 
by secretion of IL-10 (Belkaid et al., 2002), we asked whether 
observed in the total numbers of CD4+ and CD8+ T cells 
during the course of disease in DT- and PBS-treated groups, 
neither in the skin-draining LN nor in the infected ears 
(unpublished data).
Next, we asked if improved disease outcome in Langerin+ 
DC–ablated mice was associated with altered numbers of reg-
ulatory T cells (T reg cells) infiltrating the infected ears. It was 
shown previously that T reg cells are essential for the develop-
ment and maintenance of chronic cutaneous infection in   
L.  major–resistant  C57BL/6  mice  (Belkaid  et  al.,  2002;   
Mendez et al., 2004; Yurchenko et al., 2006). T reg cells ac-
cumulate at sites of infection, where they suppress anti- 
pathogen CD4+ T cell responses and consequently control 
concomitant immunity (Mendez et al., 2004). Using IL-10/ 
mice or administration of anti–IL-10 antibody led to complete 
eradication of the parasite in these mice, whereas an increase 
in the number of T reg cells promoted development of a new 
systemic infection (Belkaid et al., 2001, 2002). Interestingly, 
the important contribution of T reg cells in L. major infections 
was revealed only by using the physiological low-dose infec-
tion model (Belkaid et al., 2002; Yurchenko et al., 2006).
In this study, infiltrating ear cells of DT- and PBS-treated 
mice were isolated at the indicated time points after infection 
and analyzed for their CD4 and Foxp3 expression (Fig. 3 A). 
In the absence of Langerin+ DCs, the percentage of CD4+ 
Foxp3+ T reg cells in infected ears was significantly reduced 
in weeks 5 and 7 after Leishmania infection as compared with 
control mice (8.2 ± 1.7% vs. 14.1 ± 1.7%, n = 8 mice/group 
in week 5, P = 0.027; and 6.6 ± 1.4% vs. 11.3 ± 1.1%,   
n ≥ 10 mice/group in week 7, P = 0.015, in DT- and PBS-
treated  mice,  respectively).  Similar  results  were  obtained 
when total numbers of CD4+ Foxp3+ T reg cells infiltrating 
infected ears of DT- and PBS-treated mice were compared. 
In this case, the T reg cell number was significantly reduced 
from, for example, 11.0 ± 1.9 × 103 in the PBS group to   
3.3 ± 1.0 × 103 in DT-treated mice at week 7 (n ≥ 10, P = 
0.0029; unpublished data).
We also assessed antigen-specific IFN- production over 
time after infection of PBS- and DT-treated mice. In parallel 
with the time points of maximal differences in T reg cell 
numbers, IFN- production of LN cells was significantly in-
creased  in  DT-treated  Langerin-DTR  mice  as  compared 
with controls in weeks 5 and 7 (60 ± 15 vs. 21 ± 6 ng/ml in 
week 5, P = 0.031; and 83 ± 8 vs. 53 ± 10 ng/ml in week 7, 
P = 0.036, respectively; Fig. 3 B). Studies from Belkaid et al. 
(2000) revealed two distinct phases in the pathogenesis of cu-
taneous leishmaniasis (low dose infection). The initial silent 
phase, lasting 4–5 wk, favored dermal parasite amplification 
without lesion formation (Belkaid et al., 2000). The second 
phase corresponded to the development of lesions associated 
with an acute infiltration of inflammatory cells into the der-
mis and an expansion of T cells capable of producing IFN- 
in the draining LN, resulting in parasite killing (Belkaid et al., 
2000). Accordingly, in our study the strongest difference in 
lesion sizes was detected between weeks 7 and 12 after infec-
tion after depletion of Langerin+ DCs, together with significant 
Figure 3.  Decreased numbers of CD4+ Foxp3+ T reg cell in L. major–
infected ears of DT-treated Langerin-DTR mice. Langerin-DTR mice 
were injected i.p. with DT or PBS. After 48 h, mice were infected with  
103 L. major parasites/ear and treated weekly with DT or PBS. Ear-infiltrating 
cells were isolated at the indicated time points. After pregating on CD4+  
T cells, the percentage of Foxp3+ cells in individual ears was calculated.  
(A) Representative CD4+ Foxp3+ FACS profiles and percentages are shown. 
(B) Antigen-specific IFN- release by LN cells from infected mice was  
determined by ELISA after restimulation with SLA. (C) Mice were treated 
once with DT (DT 1×) 2 wk before Leishmania infection for selective de-
pletion of LC or weekly (DT wkly) for depletion of both LC and Langerin+ 
dDC. Total numbers of CD4+ Foxp3+ cells in infected ears are shown.  
(D) In week 7, antigen-specific cytokine release of LN cells was  
determined by ELISA. In B–D, pooled data from two or more independent 
experiments are shown (mean ± SEM, n ≥ 5 mice/group; *, P ≤ 0.05;  
**, P ≤ 0.02; ***, P ≤ 0.002).JEM VOL. 208, May 9, 2011  889
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this was also true 
for the frequency 
of Foxp3+ CD4+ 
cells  (9.5  ±  1.4 
vs.  4.2  ±  0.5%,   
P = 0.021; Fig. 4 B). These results strongly suggest that epi-
dermal LCs can expand the T reg cell population.
In a subsequent experiment, DCs were isolated using anti-
CD11c–coated  MACS  beads  from  LN  of  Langerin-DTR 
mice  treated  with  either  DT  (Langerin+  DC-depleted)  or 
PBS. As described in the previous paragraph, these DCs were 
loaded with SLA and co-cultured with CD4+ T cells (Fig. 4 C). 
After 24 h, expansion of CD25+ T cells (18.2 ± 1.4 vs. 12.7 ± 
0.6%, P = 0.012) and CD25+ Foxp3+ T cells (5.4 ± 0.4 vs. 3.4 ± 
0.5%, P = 0.011) was significantly increased when the antigen-
presenting DCs comprised Langerin+ DCs as compared with 
those lacking Langerin+ DCs (Fig. 4 D). Thus, Langerin+ 
DCs, and not Langerinneg DCs, drive the expansion of anti-
gen-specific T reg cell and, corroborating the in vivo data (Fig. 3, 
A and C), expansion of T reg cell was significantly reduced   
after Langerin+ DCs had been depleted.
Finally, to address the question of whether Langerin+ DCs 
promote T reg cell survival or whether they are able to induce 
proliferation of T reg cell, SLA-pulsed LN DCs (including/
excluding  Langerin+  DCs)  were  co-cultured  with  CD4+ 
CD25neg T cells, and induction of T reg cell was assessed after 
3 d. Absolute numbers of CD4+ CD25+ Foxp3+ and, addition-
ally, the ratio of T eff/T reg cell was strongly increased when 
Langerin+ DCs had been present in the co-culture (Fig. 4 E). 
DCs without antigen showed only a weak capacity to induce 
T reg cell.
Collectively, our results reveal a novel inhibitory role of 
LCs in orchestrating the anti-Leishmania response by sup-
pressing efficient development of protective Th1 immunity. 
there was a shift in the balance between CD4+ T eff cells 
producing IFN- and T reg cells producing IL-10 when LCs 
were absent. As shown in Fig. 3 D, IL-10 production was 
significantly reduced in LC-depleted mice as compared with 
PBS controls and mice depleted of both LCs and Langerin+ 
dDCs (0.7 ± 0.1, 1.4 ± 0.2, and 1.4 ± 0.2 ng/ml in DT 1×, 
PBS, and DT weekly treatment groups, respectively, P = 0.007 
and P = 0.02). Consequently, we detected an increase in 
the IFN-/IL-10 ratio, indicating that there were more 
CD4+ T eff cells producing IFN- and fewer CD4+ Foxp3+ 
T reg cells producing IL-10 present in the skin draining 
LN of LC-depleted as compared with LC-competent mice 
(94 ± 22 vs. 23 ± 8 in DT 1× as compared with PBS 
groups, P = 0.0068). In conclusion, conditional ablation 
of LCs resulted in enhanced protective immunity against 
physiological low-dose infection with L. major associated 
with an increased Th1 and an attenuated T reg cell im-
mune response.
Antigen-loaded Langerin+ DCs, but not Langerinneg DCs, 
preferentially expand CD4+ Foxp3+ T reg cell
Our in vivo data strongly suggest that LCs contribute to the 
expansion of T reg cell at the site of infection. To confirm these 
results, we analyzed the effect of SLA-loaded Langerin+ DCs 
on regulatory CD4+ T cells ex vivo. Epidermal cells (ECs; in-
cluding LCs) were isolated from murine ear skin and pulsed 
with  SLA.  Subsequently,  these  ECs  were  co-cultured  with 
CD4+ T cells isolated from Leishmania-infected and healed 
C57BL/6 mice. After 24 h, T cells were analyzed for their 
CD25 and Foxp3 expression using flow cytometry (Fig. 4 A). 
A significant increase of the percentage of CD25+ T cells was 
found when antigen-loaded ECs were used for antigen presen-
tation as compared with negative controls without ECs (11.5 ± 
1.0 vs. 6.2 ± 0.9%, respectively, P = 0.017; Fig. 4 B). In addition, 
Figure 4.  SLA-loaded Langerin+ DCs ex-
pand CD4+ Foxp3+ T reg cell. (A) 105 ECs were 
pulsed with SLA and co-cultured with 5 × 105 
CD4+ T cells for 24 h. Representative FACS staining 
for CD4+ CD25+ and CD4+ Foxp3+ T cells are de-
picted. (B) Pooled percentages of CD25 and Foxp3 
expression on CD4+ cells from three independent 
experiments are shown (mean ± SEM; *, P ≤ 0.05). 
(C) Enriched CD11c+ DCs from LN of DT- or PBS-
treated Langerin-DTR mice (105) were pulsed with 
SLA, and co-cultured with 5 × 105 CD4+ T cells for 
24 h. Representative FACS staining for CD4+ 
CD25+ and CD4+ CD25+ Foxp3+ T cells are pre-
sented. (D) Pooled data from three independent 
experiments are shown (mean ± SEM; *, P ≤ 0.05). 
(E) DCs alone or DCs pulsed with SLA (105) were 
co-cultured with 5 × 105 CD4+ CD25neg T cells for 
3 d. Induction of CD25 and Foxp3 on CD4 cells 
was assessed by FACS and cell numbers were cal-
culated. For calculation of the T eff/T reg cell ratio, 
numbers of total CD4 T cells (minus T reg cells) 
were divided by total numbers of CD4+ CD25+ 
Foxp3+ T reg cells. One representative of three 
experiments is shown. In B, D, and E, Ø = T cells 
without APC. In D and E, black bars indicate  
DCs containing Langerin+ cells and white  
bars indicate DCs prepared from DT-treated  
Langerin-DTR mice.890 Regulatory function of LCs in leishmaniasis | Kautz-Neu et al.
cell suspensions were prepared. DC isolation was performed using MACS 
CD11c MicroBeads (Miltenyi Biotec) according to the manufacturer’s in-
structions. For isolation of CD4+ T cells, LN cells from L. major–infected 
and  healed  C57BL/6  were  collected  and  enriched  using  MACS  CD4+  
MicroBeads (Miltenyi Biotec). For isolation of CD4+ CD25 T cells, LN 
cells from L. major–infected and healed C57BL/6 were collected and en-
riched using MACS CD4+ CD25+ regulatory T cell isolation kit (Miltenyi 
Biotec), finally using the CD4+ CD25 cell fraction.
Isolation of EC and dermal cell suspensions. ECs were prepared   
from ear skin by trypsinization (0.5% trypsin [GE Healthcare] in HBSS   
[BioWhittaker] for 30 min at 37°C) and dissociation of epidermal sheets by 
gentle pipetting in HBSS/0.05% DNase/30% FCS. Cell clumps were removed 
by passing the cell suspension through a 70-µm nylon mesh.
Dermal cell suspensions were prepared from ear skin after removal of the 
epidermis. Dermal tissue was minced into small pieces and digested for 2 h   
at 37°C with a solution of HBSS, 0.5% Collagenase (Sigma-Aldrich), 0.05%   
DNase, and 2% FCS. Dermal Langerin+ cells were identified by expression of 
CD11c, Langerin, and CD103.
Antibodies and flow cytometry. The following antibodies were purchased 
from BD: PerCP-Cy5.5 rat anti–mouse CD8 (53–6.7), PE rat anti–mouse 
CD4 (L3T4), and FITC rat anti–mouse CD25 (7D4). Intracellular APC anti–
mouse Foxp3 (FJK-16s; eBioscience) staining was performed using eBioscience 
reagents according to the manufacturer’s protocol. Single cell suspensions were 
stained first for surface markers, followed by a permeabilization step and stain-
ing for Foxp3. For analysis of skin and LN DCs the following antibodies were 
used: Pacific blue anti–mouse MHCII (M5/114.15.2; BioLegend), PerCPCy5.5 
anti–mouse CD103 (2E7; BioLegend), APC anti–mouse CD11c (HL3; BD), 
PE anti–mouse CD11c (N418; eBioscience), and Alexa Fluor 488 Langerin 
(929F3.01; Dendritics) for intracellular staining. Cells were analyzed using a 
FACSCalibur or LSRII cytometer (BD) and FlowJo software (Tree Star).
BM chimeras. Langerin DTR and C57BL/6 donor BM was used to reconsti-
tute lethally irradiated (9 Gray) recipient mice (C57BL/6 and Langerin-DTR, 
respectively). The resulting chimeric mice were allowed to reconstitute their 
hematopoietic compartment for at least 6 wk before analysis. Subsequently, 
mice were infected with physiologically relevant low dose inocula of L. major 
and lesion development was assessed weekly.
Statistical analysis. Statistical analysis was performed using StatView software 
and Student’s t test.
Online supplemental material. Fig. S1 shows the depletion of Langerin+ 
DCs in the epidermis, dermis, and LN of Langerin-DTR mice 48 h after 
administration of DT. Fig. S2 illustrates the course of disease in high- 
dose–infected Langerin-DTR mice with and without DT treatment. Fig. S3 
depicts the selective depletion/slow reconstitution of LCs 2 wk after DT ad-
ministration and confirms specific depletion of LCs and Langerin+ dDCs   
in different BM chimeras. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20102318/DC1.
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In addition, LCs favor the recruitment of T reg cell to the 
site of infection, resulting in aggravated disease. Mice on a 
Leishmania-resistant C57BL/6 background exhibit attenuated 
disease in the absence of epidermal LCs, suggesting that the 
parasites may possess well adapted strategies to exploit the 
regulatory capacities of LCs to escape efficient immune sur-
veillance. Nevertheless, LC-competent C57BL/6 mice still 
display a self-healing phenotype, arguing that the presence of 
LCs is insufficient to mediate disease susceptibility in this 
strain. Our data are also relevant for DC-based vaccination strate-
gies, as infected LCs may induce Leishmania-specific immuno-
suppression rather than parasite control. Indeed, our findings 
suggest that efforts to selectively deplete LCs from the skin or 
avoid targeting LCs during vaccination may benefit patients 
suffering from (cutaneous) leishmaniasis.
MATERIALS AND METHODS
Mice. Langerin-DTR mice (C57BL/6) were bred as heterozygotes (Bennett   
et al., 2005) and housed under specific pathogen-free conditions in the ani-
mal care facility in Mainz. Animal experimentation was conducted in accor-
dance with current federal guidelines and approved by the national authorities 
(Landesuntersuchungsamt, LUA 23 170–07/ G07-1-022).
Parasites and infection. Metacyclic promastigotes of L. major clone VI 
(MHOM/IL/80/Friedlin) were prepared as described previously (von Stebut   
et al., 2003). Groups of three to five mice were infected with low-dose (103) 
inocula by intradermal injection into ear skin. In some experiments, DT 
(Sigma-Aldrich) was diluted in sterile PBS, and 26 ng/g body weight was 
injected i.p. as indicated. Lesion volumes were measured weekly in three di-
mensions and are reported as ellipsoids: [(a/2 × b/2 × c/2) × 4/3]. Para-
sites present in lesional tissue were enumerated using a limiting dilution assay 
as previously described (von Stebut et al., 2003).
Preparation of epidermal sheets. The dorsal and ventral halves of mouse 
ears were split mechanically and placed dermis down into Petri dishes con-
taining 0.5 M NH4SCN dissolved in 0.1 M Na-KHPO4 buffer at 37°C for 
20 min. Epidermis was removed, fixed with ice-cold acetone, and rehy-
drated in PBS. Epidermal sheets were stained with FITC anti–mouse I-A/I-E 
(2G9; BD) for 1.5 h at room temperature. After washing with PBS,   
the epidermal sheets were mounted on slides with Fluorescent Mounting   
Medium (Dako). Images were analyzed at room temperature using a fluorescent 
microscope (Axiovert S100; Carl Zeiss).
Cytokine profiles of infected mice. For measurement of antigen-specific cyto-
kine production, retroauricular LNs were recovered and single cell suspensions 
were prepared. One million LN cells/200 µl complete RPMI 1640 (BioWhit-
taker) were added to 96-well plates in the presence of 25 µg/ml SLA. Super-
natants were harvested 48 h after stimulation and assayed using ELISAs specific 
for IL-12p40 and IFN- (R&D Systems), as well as IL-4 and IL-10 (BD).
Cell isolation from infected mouse ears. Ears infected with L. major 
were excised, soaked in 70% ethanol, and washed with PBS. The ears were 
split into halves and placed in 0.5 mg/ml liberase (Sigma-Aldrich) diluted in 
RPMI 1640 with 5% penicillin/streptomycin for 1.5 h at 37°C. Liberase was 
inactivated by adding complete RPMI 1640 containing 5% FCS. The ears 
were put into 50 µM Medicon homogenizers (BD) with 1 ml of complete 
RPMI 1640 and homogenized in a Medimachine (BD) for 7 min. The   
homogenized ears were then passed through a 70-µm-pore size filter and 
centrifuged at 200 g for 8 min. Cells were resuspended in PBS and labeled 
with antibodies for flow cytometry.
DC and CD4+ T cell isolation from LN cells. For DC isolation, LNs 
from DT- or PBS-treated Langerin-DTR mice were harvested and single JEM VOL. 208, May 9, 2011  891
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